

Yongzhuo Huang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/989557/publications.pdf>

Version: 2024-02-01

138
papers

8,362
citations

46918

47
h-index

53109

85
g-index

148
all docs

148
docs citations

148
times ranked

11538
citing authors

#	ARTICLE	IF	CITATIONS
1	Recent progress in drug delivery. <i>Acta Pharmaceutica Sinica B</i> , 2019, 9, 1145-1162.	5.7	529
2	Blood-Brain-Barrier-Penetrating Albumin Nanoparticles for Biomimetic Drug Delivery via Albumin-Binding Protein Pathways for Antiglioma Therapy. <i>ACS Nano</i> , 2016, 10, 9999-10012.	7.3	384
3	The Endotoxin Delivery Protein HMGB1 Mediates Caspase-11-Dependent Lethality in Sepsis. <i>Immunity</i> , 2018, 49, 740-753.e7.	6.6	377
4	Macrophage-Membrane-Coated Nanoparticles for Tumor-Targeted Chemotherapy. <i>Nano Letters</i> , 2018, 18, 1908-1915.	4.5	289
5	Fusogenic Reactive Oxygen Species Triggered Charge-Reversal Vector for Effective Gene Delivery. <i>Advanced Materials</i> , 2016, 28, 1743-1752.	11.1	288
6	The artificial peroxidase activity of magnetic iron oxide nanoparticles and its application to glucose detection. <i>Biomaterials</i> , 2009, 30, 4716-4722.	5.7	274
7	Intracellularly Acid-Switchable Multifunctional Micelles for Combinational Photo/Chemotherapy of the Drug-Resistant Tumor. <i>ACS Nano</i> , 2016, 10, 3496-3508.	7.3	267
8	Recent progress in microRNA delivery for cancer therapy by non-viral synthetic vectors. <i>Advanced Drug Delivery Reviews</i> , 2015, 81, 142-160.	6.6	208
9	Dual-targeting biomimetic delivery for anti-glioma activity via remodeling the tumor microenvironment and directing macrophage-mediated immunotherapy. <i>Chemical Science</i> , 2018, 9, 2674-2689.	3.7	196
10	Dual-Targeting Magnetic PLGA Nanoparticles for Codelivery of Paclitaxel and Curcumin for Brain Tumor Therapy. <i>ACS Applied Materials & Interfaces</i> , 2016, 8, 32159-32169.	4.0	184
11	TAT-modified nanosilver for combating multidrug-resistant cancer. <i>Biomaterials</i> , 2012, 33, 6155-6161.	5.7	182
12	Curb challenges of the "Trojan Horse" approach: Smart strategies in achieving effective yet safe cell-penetrating peptide-based drug delivery. <i>Advanced Drug Delivery Reviews</i> , 2013, 65, 1299-1315.	6.6	175
13	Co-administration of protein drugs with gold nanoparticles to enable percutaneous delivery. <i>Biomaterials</i> , 2010, 31, 9086-9091.	5.7	172
14	Targeting lipid metabolism to overcome EMT-associated drug resistance via integrin β 3/FAK pathway and tumor-associated macrophage repolarization using legumain-activatable delivery. <i>Theranostics</i> , 2019, 9, 265-278.	4.6	141
15	Inhibition of metastasis and growth of breast cancer by pH-sensitive poly (β -amino ester) nanoparticles co-delivering two siRNA and paclitaxel. <i>Biomaterials</i> , 2015, 48, 1-15.	5.7	134
16	Reprogramming Tumor Immune Microenvironment (TIME) and Metabolism via Biomimetic Targeting Codelivery of Shikonin/JQ1. <i>Nano Letters</i> , 2019, 19, 2935-2944.	4.5	134
17	Dual-Targeting to Cancer Cells and M2 Macrophages via Biomimetic Delivery of Mannosylated Albumin Nanoparticles for Drug-Resistant Cancer Therapy. <i>Advanced Functional Materials</i> , 2017, 27, 1700403.	7.8	118
18	Co-delivery of doxorubicin and RNA using pH-sensitive poly (β -amino ester) nanoparticles for reversal of multidrug resistance of breast cancer. <i>Biomaterials</i> , 2014, 35, 6047-6059.	5.7	113

#	ARTICLE	IF	CITATIONS
19	Disulfiram Copper Nanoparticles Prepared with a Stabilized Metal Ion Ligand Complex Method for Treating Drug-Resistant Prostate Cancers. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 41118-41128.	4.0	109
20	Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer. <i>Cancer Biology and Medicine</i> , 2017, 14, 212.	1.4	98
21	Low-molecular-weight protamine-modified PLGA nanoparticles for overcoming drug-resistant breast cancer. <i>Journal of Controlled Release</i> , 2014, 192, 47-56.	4.8	93
22	Multifunctional drug delivery system for targeting tumor and its acidic microenvironment. <i>Journal of Controlled Release</i> , 2012, 161, 884-892.	4.8	91
23	Reprogramming Tumor-Associated Macrophages To Reverse EGFR ^{T790M} Resistance by Dual-Targeting Codelivery of Gefitinib/Vorinostat. <i>Nano Letters</i> , 2017, 17, 7684-7690.	4.5	90
24	Codelivery of dihydroartemisinin and doxorubicin in mannosylated liposomes for drug-resistant colon cancer therapy. <i>Acta Pharmacologica Sinica</i> , 2017, 38, 885-896.	2.8	87
25	Co-Delivery of Trichosanthin and Albendazole by Nano-Self-Assembly for Overcoming Tumor Multidrug-Resistance and Metastasis. <i>ACS Applied Materials & Interfaces</i> , 2017, 9, 26648-26664.	4.0	86
26	Codelivery of Sorafenib and Curcumin by Directed Self-Assembled Nanoparticles Enhances Therapeutic Effect on Hepatocellular Carcinoma. <i>Molecular Pharmaceutics</i> , 2015, 12, 922-931.	2.3	82
27	Macrophage-based nanotherapeutic strategies in ulcerative colitis. <i>Journal of Controlled Release</i> , 2020, 320, 363-380.	4.8	82
28	Glioma selectivity of magnetically targeted nanoparticles: A role of abnormal tumor hydrodynamics. <i>Journal of Controlled Release</i> , 2007, 122, 315-323.	4.8	80
29	Epirubicin-Loaded Superparamagnetic Iron-Oxide Nanoparticles for Transdermal Delivery: Cancer Therapy by Circumventing the Skin Barrier. <i>Small</i> , 2015, 11, 239-247.	5.2	73
30	Albumin Biomimetic Nanocorona Improves Tumor Targeting and Penetration for Synergistic Therapy of Metastatic Breast Cancer. <i>Advanced Functional Materials</i> , 2017, 27, 1605679.	7.8	73
31	Doxorubicin and Lapatinib Combination Nanomedicine for Treating Resistant Breast Cancer. <i>Molecular Pharmaceutics</i> , 2014, 11, 2600-2611.	2.3	72
32	Metabolic modulation via mTOR pathway and anti-angiogenesis remodels tumor microenvironment using PD-L1-targeting codelivery. <i>Biomaterials</i> , 2020, 255, 120187.	5.7	72
33	Biomimetic albumin-modified gold nanorods for photothermo-chemotherapy and macrophage polarization modulation. <i>Acta Pharmaceutica Sinica B</i> , 2018, 8, 74-84.	5.7	70
34	Remodeling tumor immune microenvironment (TIME) for glioma therapy using multi-targeting liposomal codelivery. , 2020, 8, e000207.		70
35	PEGylated synthetic surfactant vesicles (Niosomes): novel carriers for oligonucleotides. <i>Journal of Materials Science: Materials in Medicine</i> , 2008, 19, 607-614.	1.7	68
36	The magnetophoretic mobility and superparamagnetism of core-shell iron oxide nanoparticles with dual targeting and imaging functionality. <i>Biomaterials</i> , 2010, 31, 5842-5848.	5.7	67

#	ARTICLE	IF	CITATIONS
37	Combination therapy based on nano codelivery for overcoming cancer drug resistance. <i>Medicine in Drug Discovery</i> , 2020, 6, 100024.	2.3	66
38	A Prodrug-type, MMP-2-targeting Nanoprobe for Tumor Detection and Imaging. <i>Theranostics</i> , 2015, 5, 787-795.	4.6	61
39	Remodeling Tumor-Associated Macrophages and Neovascularization Overcomes EGFR ^{T790M} -Associated Drug Resistance by PD-1 Nanobody-Mediated Codelivery. <i>Small</i> , 2018, 5.2 14, e1802372.		60
40	The use of low molecular weight protamine chemical chimera to enhance monomeric insulin intestinal absorption. <i>Biomaterials</i> , 2013, 34, 7733-7743.	5.7	59
41	Nose-to-brain delivery of macromolecules mediated by cell-penetrating peptides. <i>Acta Pharmaceutica Sinica B</i> , 2016, 6, 352-358.	5.7	59
42	Intein-mediated site-specific synthesis of tumor-targeting protein delivery system: Turning PEG dilemma into prodrug-like feature. <i>Biomaterials</i> , 2017, 116, 57-68.	5.7	57
43	Targeting death receptors for drug-resistant cancer therapy: Codelivery of pTRAIL and monensin using dual-targeting and stimuli-responsive self-assembling nanocomposites. <i>Biomaterials</i> , 2018, 158, 56-73.	5.7	57
44	Roles of Albumin-Binding Proteins in Cancer Progression and Biomimetic Targeted Drug Delivery. <i>ChemBioChem</i> , 2018, 19, 1796-1805.	1.3	57
45	A Trojan horse biomimetic delivery strategy using mesenchymal stem cells for PDT/PTT therapy against lung melanoma metastasis. <i>Biomaterials Science</i> , 2020, 8, 1160-1170.	2.6	52
46	BBB-penetrating codelivery liposomes treat brain metastasis of non-small cell lung cancer with EGFR ^{T790M} mutation. <i>Theranostics</i> , 2020, 10, 6122-6135.	4.6	52
47	Microneedle-Assisted, DC-Targeted Codelivery of pTRP-2 and Adjuvant of Paclitaxel for Transcutaneous Immunotherapy. <i>Small</i> , 2017, 13, 1700666.	5.2	50
48	Liposomal Codelivery of Doxorubicin and Andrographolide Inhibits Breast Cancer Growth and Metastasis. <i>Molecular Pharmaceutics</i> , 2018, 15, 1618-1626.	2.3	49
49	Antiglioma via regulating oxidative stress and remodeling tumor-associated macrophage using lactoferrin-mediated biomimetic codelivery of simvastatin/fenretinide. <i>Journal of Controlled Release</i> , 2018, 287, 12-23.	4.8	49
50	Hydrothermal Synthesis and Biocompatibility Study of Highly Crystalline Carbonated Hydroxyapatite Nanorods. <i>Nanoscale Research Letters</i> , 2015, 10, 1018.	3.1	48
51	Synthetic Skin-Permeable Proteins Enabling Needleless Immunization. <i>Angewandte Chemie - International Edition</i> , 2010, 49, 2724-2727.	7.2	47
52	Cell-penetrating peptide-modified PLGA nanoparticles for enhanced nose-to-brain macromolecular delivery. <i>Macromolecular Research</i> , 2013, 21, 435-441.	1.0	47
53	Natural Brain Penetration Enhancer-Modified Albumin Nanoparticles for Glioma Targeting Delivery. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 30201-30213.	4.0	47
54	Lactoferrin-mediated macrophage targeting delivery and patchouli alcohol-based therapeutic strategy for inflammatory bowel diseases. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 1966-1976.	5.7	46

#	ARTICLE	IF	CITATIONS
55	Magnetic Nanoparticles for Tumor Imaging and Therapy: A So-Called Theranostic System. <i>Pharmaceutical Research</i> , 2013, 30, 2445-2458.	1.7	45
56	Microneedle-assisted dendritic cell-targeted nanoparticles for transcutaneous DNA immunization. <i>Polymer Chemistry</i> , 2015, 6, 373-379.	1.9	45
57	Identification of Epigallocatechin-3- Gallate as an Inhibitor of Phosphoglycerate Mutase 1. <i>Frontiers in Pharmacology</i> , 2017, 8, 325.	1.6	45
58	Glioma Dual-Targeting Nanohybrid Protein Toxin Constructed by Intein-Mediated Site-Specific Ligation for Multistage Booster Delivery. <i>Theranostics</i> , 2017, 7, 3489-3503.	4.6	43
59	TRAIL-based gene delivery and therapeutic strategies. <i>Acta Pharmacologica Sinica</i> , 2019, 40, 1373-1385.	2.8	42
60	High-Yield Synthesis of Monomeric LMWP(CPP)-siRNA Covalent Conjugate for Effective Cytosolic Delivery of siRNA. <i>Theranostics</i> , 2017, 7, 2495-2508.	4.6	40
61	Preparation and Characterization of Liposomes Encapsulating Chitosan Nanoparticles. <i>Biological and Pharmaceutical Bulletin</i> , 2005, 28, 387-390.	0.6	39
62	Prodrug-Like, PEGylated Protein Toxin Trichosanthin for Reversal of Chemoresistance. <i>Molecular Pharmaceutics</i> , 2017, 14, 1429-1438.	2.3	39
63	Tat-functionalized Ag-Fe ₃ O ₄ nano-composites as tissue-penetrating vehicles for tumor magnetic targeting and drug delivery. <i>Acta Pharmaceutica Sinica B</i> , 2018, 8, 956-968.	5.7	38
64	Magnetism-mediated targeting hyperthermia-immunotherapy in cold tumor with CSF1R inhibitor. <i>Theranostics</i> , 2021, 11, 6860-6872.	4.6	36
65	ATTEMPTS System: A Macromolecular Prodrug Strategy for Cancer Drug Delivery. <i>Current Pharmaceutical Design</i> , 2010, 16, 2369-2376.	0.9	35
66	Polysorbate cationic synthetic vesicle for gene delivery. <i>Journal of Biomedical Materials Research - Part A</i> , 2011, 96A, 513-519.	2.1	35
67	Magnetic Nanoparticles for MRI of Brain Tumors. <i>Current Pharmaceutical Biotechnology</i> , 2012, 13, 2403-2416.	0.9	35
68	Cell-Penetrating Apoptotic Peptide/p53 DNA Nanocomplex as Adjuvant Therapy for Drug-Resistant Breast Cancer. <i>Molecular Pharmaceutics</i> , 2014, 11, 3352-3360.	2.3	35
69	Disulfiram-loaded lactoferrin nanoparticles for treating inflammatory diseases. <i>Acta Pharmacologica Sinica</i> , 2021, 42, 1913-1920.	2.8	33
70	Cationic liposomes modified with non-ionic surfactants as effective non-viral carrier for gene transfer. <i>Colloids and Surfaces B: Biointerfaces</i> , 2006, 49, 158-164.	2.5	31
71	Alginate-Chitosan-PLGA Composite Microspheres Enabling Single-Shot Hepatitis B Vaccination. <i>AAPS Journal</i> , 2010, 12, 519-524.	2.2	30
72	Green synthesis of hyaluronic acid-based silver nanoparticles and their enhanced delivery to CD44 ⁺ cancer cells. <i>RSC Advances</i> , 2015, 5, 43733-43740.	1.7	30

#	ARTICLE	IF	CITATIONS
73	Biomimetic metal-organic nanoparticles prepared with a 3D-printed microfluidic device as a novel formulation for disulfiram-based therapy against breast cancer. <i>Applied Materials Today</i> , 2020, 18, 100492.	2.3	29
74	Cell-penetrating albumin conjugates for enhanced doxorubicin delivery. <i>Polymer Chemistry</i> , 2013, 4, 4584.	1.9	27
75	A mannosylated PEIâ€‘CPP hybrid for TRAIL gene targeting delivery for colorectal cancer therapy. <i>Polymer Chemistry</i> , 2017, 8, 5275-5285.	1.9	27
76	Biomimetic codelivery overcomes osimertinib-resistant NSCLC and brain metastasis via macrophage-mediated innate immunity. <i>Journal of Controlled Release</i> , 2021, 329, 1249-1261.	4.8	27
77	In vivo delivery of cell-permeable antisense hypoxia-inducible factor 1Î± oligonucleotide to adipose tissue reduces adiposity in obese mice. <i>Journal of Controlled Release</i> , 2012, 161, 1-9.	4.8	26
78	Molecularâ€‘Dynamicsâ€‘Simulationâ€‘Driven Design of a Proteaseâ€‘Responsive Probe for Inâ€‘Vivo Tumor Imaging. <i>Advanced Materials</i> , 2014, 26, 8174-8178.	11.1	26
79	Proteaseâ€‘Activatable Hybrid Nanoprobe for Tumor Imaging. <i>Advanced Functional Materials</i> , 2014, 24, 5443-5453.	7.8	26
80	Recombinant TAT-gelatin fusion toxin: Synthesis and characterization of heparin/protamine-regulated cell transduction. <i>Journal of Biomedical Materials Research - Part A</i> , 2015, 103, 409-419.	2.1	26
81	Skin-permeable quaternary nanoparticles with layer-by-layer structure enabling improved gene delivery. <i>Journal of Materials Chemistry</i> , 2012, 22, 10029.	6.7	25
82	Neutralization of SARS-CoV-2 pseudovirus using ACE2-engineered extracellular vesicles. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 1523-1533.	5.7	25
83	PTD-Modified ATTEMPTS for Enhanced Toxin-based Cancer Therapy: An In Vivo Proof-of-Concept Study. <i>Pharmaceutical Research</i> , 2015, 32, 2690-703.	1.7	24
84	Preparation and Characterization of Gelatin-Melittin Fusion Biotxin for Synergistically Enhanced Anti-Tumor Activity. <i>Pharmaceutical Research</i> , 2016, 33, 2218-2228.	1.7	24
85	Menthol-modified BSA nanoparticles for glioma targeting therapy using an energy restriction strategy. <i>NPG Asia Materials</i> , 2019, 11, .	3.8	24
86	Remodeling â€‘coldâ€‘tumor immune microenvironment via epigenetic-based therapy using targeted liposomes with in situ formed albumin corona. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 2057-2073.	5.7	24
87	A drug-free nanozyme for mitigating oxidative stress and inflammatory bowel disease. <i>Journal of Nanobiotechnology</i> , 2022, 20, 107.	4.2	24
88	Poly-Î³-glutamic acid-based GGT-targeting and surface camouflage strategy for improving cervical cancer gene therapy. <i>Journal of Materials Chemistry B</i> , 2017, 5, 1315-1327.	2.9	23
89	Anti-PD-L1 mediating tumor-targeted codelivery of liposomal irinotecan/JQ1 for chemo-immunotherapy. <i>Acta Pharmacologica Sinica</i> , 2021, 42, 1516-1523.	2.8	23
90	An in situ-forming, solid lipid/PLGA hybrid implant for long-acting antipsychotics. <i>Soft Matter</i> , 2011, 7, 5873.	1.2	22

#	ARTICLE	IF	CITATIONS
91	Nano-Structural Effects on Gene Transfection: Large, Botryoid-Shaped Nanoparticles Enhance DNA Delivery via Macropinocytosis and Effective Dissociation. <i>Theranostics</i> , 2019, 9, 1580-1598.	4.6	22
92	Nuclear-targeting TAT-PEG-Asp8-doxorubicin polymeric nanoassembly to overcome drug-resistant colon cancer. <i>Acta Pharmacologica Sinica</i> , 2016, 37, 1110-1120.	2.8	21
93	Cell-penetrating peptide-based non-invasive topical delivery systems. <i>Journal of Pharmaceutical Investigation</i> , 2018, 48, 77-87.	2.7	21
94	Nanotechnology-Based Histone Deacetylase Inhibitors for Cancer Therapy. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 400.	1.8	21
95	The ATTEMPTS delivery systems for macromolecular drugs. <i>Expert Opinion on Drug Delivery</i> , 2008, 5, 1255-1266.	2.4	20
96	Specific down regulation of 3T3-L1 adipocyte differentiation by cell-permeable antisense HIF1 α -oligonucleotide. <i>Journal of Controlled Release</i> , 2010, 144, 82-90.	4.8	20
97	Overcoming oral insulin delivery barriers: application of cell penetrating peptide and silica-based nanoporous composites. <i>Frontiers of Chemical Science and Engineering</i> , 2013, 7, 9-19.	2.3	20
98	Application of Monodisperse PEGs in Pharmaceuticals: Monodisperse Polidocanols. <i>Molecular Pharmaceutics</i> , 2017, 14, 3473-3479.	2.3	20
99	Improved method for synthesis of low molecular weight protamine α siRNA conjugate. <i>Acta Pharmaceutica Sinica B</i> , 2018, 8, 116-126.	5.7	20
100	Transcutaneous delivery of DNA/mRNA for cancer therapeutic vaccination. <i>Journal of Gene Medicine</i> , 2019, 21, e3089.	1.4	19
101	Biomimetic camouflage delivery strategies for cancer therapy. <i>Nanoscale</i> , 2021, 13, 8693-8706.	2.8	19
102	Remodeling immune microenvironment in periodontitis using resveratrol liposomes as an antibiotic-free therapeutic strategy. <i>Journal of Nanobiotechnology</i> , 2021, 19, 429.	4.2	19
103	Smart Cell-Penetrating Peptide-Based Techniques for Intracellular Delivery of Therapeutic Macromolecules. <i>Advances in Protein Chemistry and Structural Biology</i> , 2018, 112, 183-220.	1.0	18
104	Genetically-engineered protein prodrug-like nanoconjugates for tumor-targeting biomimetic delivery via a SHEATH strategy. <i>Nanoscale</i> , 2019, 11, 611-621.	2.8	18
105	Advances on Tumor-Targeting Delivery of Cytotoxic Proteins. <i>ACS Pharmacology and Translational Science</i> , 2020, 3, 107-118.	2.5	18
106	Cell-Penetrating Peptide-Mediated Topical Delivery of Biomacromolecular Drugs. <i>Current Pharmaceutical Biotechnology</i> , 2014, 15, 231-239.	0.9	18
107	A novel tumor-targeting treatment strategy uses energy restriction via co-delivery of albendazole and nanosilver. <i>Nano Research</i> , 2018, 11, 4507-4523.	5.8	17
108	A hybrid thermo-sensitive chitosan gel for sustained release of Meloxicam. <i>Journal of Biomaterials Science, Polymer Edition</i> , 2008, 19, 1239-1247.	1.9	16

#	ARTICLE	IF	CITATIONS
109	Recombinant cancer nanovaccine for targeting tumor-associated macrophage and remodeling tumor microenvironment. <i>Nano Today</i> , 2021, 40, 101244.	6.2	16
110	Downregulation of survivin expression and enhanced chemosensitivity of MCF-7 cells to adriamycin by PDMAE/survivin shRNA complex nanoparticles. <i>International Journal of Pharmaceutics</i> , 2011, 405, 188-195.	2.6	15
111	Co-delivery of Cell-permeable Chimeric Apoptosis AVPIR ₈ Peptide/p53 DNA for Cocktail Therapy. <i>Advanced Functional Materials</i> , 2013, 23, 6068-6075.	7.8	15
112	Pluronic L61 as a long-circulating modifier for enhanced liposomal delivery of cancer drugs. <i>Polymer Chemistry</i> , 2013, 4, 2958.	1.9	14
113	Teaching new tricks to old dogs: A review of drug repositioning of disulfiram for cancer nanomedicine. <i>View</i> , 2021, 2, 20200127.	2.7	14
114	Tandem-multimeric F3-gelonin fusion toxins for enhanced anti-cancer activity for prostate cancer treatment. <i>International Journal of Pharmaceutics</i> , 2017, 524, 101-110.	2.6	12
115	CPP-mediated Protein Delivery in a Noncovalent Form: Proof-of-Concept for Percutaneous and Intranasal Delivery. <i>Protein and Peptide Letters</i> , 2014, 21, 1129-1136.	0.4	12
116	Brain-targeting biomimetic nanoparticles for codelivery of celastrol and LY2157299 for reversing glioma immunosuppression. <i>International Journal of Pharmaceutics</i> , 2022, 619, 121709.	2.6	12
117	Anti-alcoholism drug disulfiram for targeting glioma energy metabolism using BBB-penetrating delivery of fixed-dose combination. <i>Nano Today</i> , 2022, 44, 101448.	6.2	12
118	Gene Delivery: Fusogenic Reactive Oxygen Species Triggered Charge-Reversal Vector for Effective Gene Delivery (<i>Adv. Mater.</i> 9/2016). <i>Advanced Materials</i> , 2016, 28, 1714-1714.	11.1	11
119	Deformable liposomal codelivery of vorinostat and simvastatin promotes antitumor responses through remodeling tumor microenvironment. <i>Biomaterials Science</i> , 2020, 8, 7166-7176.	2.6	11
120	Improved Protein Toxin Delivery Based on ATTEMPTS Systems. <i>Current Drug Targets</i> , 2018, 19, 380-392.	1.0	11
121	Inhaled heparin polysaccharide nanodecoy against SARS-CoV-2 and variants. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 3187-3194.	5.7	11
122	An injectable hybrid nanoparticle-in-oil-in-water submicron emulsion for improved delivery of poorly soluble drugs. <i>Nanoscale Research Letters</i> , 2012, 7, 219.	3.1	10
123	Template synthesis of PMAA@chitosan hollow nanorods for docetaxel delivery. <i>Polymer Chemistry</i> , 2013, 4, 2489.	1.9	10
124	Heparin-Regulated Prodrug-Type Macromolecular Theranostic Systems for Cancer Therapy. <i>Nanotheranostics</i> , 2017, 1, 114-130.	2.7	10
125	Genetically-engineered "all-in-one" vaccine platform for cancer immunotherapy. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 3622-3635.	5.7	9
126	Drug Delivery and Reversal of MDR. <i>Molecular Pharmaceutics</i> , 2014, 11, 2493-2494.	2.3	8

#	ARTICLE	IF	CITATIONS
127	Trained Macrophage Bioreactor for Penetrating Delivery of Fused Antitumor Protein. ACS Applied Materials & Interfaces, 2019, 11, 23018-23025.	4.0	8
128	Nanotherapeutic macrophage-based immunotherapy for the peritoneal carcinomatosis of lung cancer. Nanoscale, 2022, 14, 2304-2315.	2.8	8
129	Low molecular weight protamine/insulin formulation with potential to attenuate protamine-masqueraded insulin allergy. Macromolecular Research, 2011, 19, 1224-1226.	1.0	7
130	The intra-brain distribution of brain targeting delivery systems. , 2019, , 409-438.		7
131	Ultrasound-mediated targeted microbubbles: a new vehicle for cancer therapy. Frontiers of Chemical Science and Engineering, 2013, 7, 20-28.	2.3	6
132	Bioreducible Micelles with Endosomal Buffering and Multidrug Resistance-Reversing Function Enhance Anti-Tumor Efficacy of Doxorubicin. Journal of Biomedical Nanotechnology, 2015, 11, 1764-1775.	0.5	6
133	Lipid Metabolism Regulation Based on Nanotechnology for Enhancement of Tumor Immunity. Frontiers in Pharmacology, 2022, 13, 840440.	1.6	6
134	Editorial (Thematic Issue: "Cell-penetrating Peptides and Drug Delivery"). Current Pharmaceutical Biotechnology, 2014, 15, 191-191.	0.9	4
135	Cancer nanobiotechnology. Acta Pharmacologica Sinica, 2017, 38, 735-737.	2.8	4
136	Advances on Delivery of Cytotoxic Enzymes as Anticancer Agents. Molecules, 2022, 27, 3836.	1.7	2
137	Nanotechnology-based targeted drug delivery systems and drug resistance in colorectal cancer. , 2020, , 173-198.		1
138	Introduction to biomimetic therapeutics. Biomaterials Science, 2020, 8, 1017-1019.	2.6	0